Screener
Regenxbio RGNX Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Regenxbio in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Regenxbio’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336725
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Deferred revenue | (4,109) | 37,666 |
| Operating lease liabilities | (4,640) | (4,396) |
| Other liabilities | (152) | (2,971) |
| Net cash used in operating activities | (138,424) | (15,713) |
| Cash flows from investing activities | ||
| Purchases of marketable debt securities | (9,839) | (230,298) |
| Maturities of marketable debt securities | 136,882 | 136,020 |
| Sales of marketable debt securities | 11,465 | — |
Item 1. Financial Statements.
FAQ
- What is Regenxbio's operating cash flow?
- Regenxbio (RGNX) reported operating cash flow of -$62.24M in Q2 2026.
- How has Regenxbio's operating cash flow changed year-over-year?
- Regenxbio's operating cash flow decreased by 26.1% year-over-year, from -$49.34M to -$62.24M.
- What is the long-term trend for Regenxbio's operating cash flow?
- Over 4 years (2021 to 2025), Regenxbio's operating cash flow has grown at a -13.2% compound annual growth rate (CAGR), from $218.88M to -$123.96M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Regenxbio's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude